• Explore /
  • Poster
  • / Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902).

Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902).

Abstract Poster

Authors

null

Evanthia Galanis

Mayo Clinic, Rochester, MN

Evanthia Galanis , S. Keith Anderson , C. Ryan Miller , Jann Nagina Sarkaria , Kurt A. Jaeckle , Jan C. Buckner , Keith L. Ligon , Karla V. Ballman , Dennis Frederic Moore Jr., Manmeet Singh Ahluwalia , Eudocia Quant Lee , Elizabeth Robins Gerstner , Glenn Jay Lesser , Michael Prados , Stuart A. Grossman , Caterina Giannini , Patrick Y. Wen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Clinical Trial Registration Number

NCT00731731

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 2030)

DOI

10.1200/jco.2014.32.15_suppl.2030

Abstract #

2030

Poster Bd #

21

Abstract Disclosures

Similar Posters

First Author: Evanthia Galanis

First Author: Mustafa Khasraw

First Author: V. Verschaeve

First Author: A. M. P. Omuro